Ozempic (semaglutide) and Victoza (liraglutide) are prescription drugs used to treat type 2 diabetes and reduce the risk of cardiovascular problems. Both drugs come as an injection. Ozempic is not ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

According to the researchers, the findings indicated that the two drugs may have neuroprotective effects for people without diabetes and may help slow the rate of cognitive decline in Alzheimer's ...

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...

Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, ...

The injectable prescription medicine is primarily used to treat type 2 diabetes. Fetterman was prescribed the medication in July 2024. "As a stroke survivor, I was interested in studies showing ...

More than 2 out of 5 American adults are obese, according to the Centers for Disease Control. With this figure in mind, it's ...

Weight-reducing diabetes medications, specifically SGLT2 inhibitors and GLP-1 receptor agonists, may increase fall risk in type 2 diabetes patients due to potential muscle mass loss.

Imagine a world where managing type 2 diabetes doesn't involve needles. A new experimental pill might just change the game, ...

A daily pill from Eli Lilly lowered blood sugar levels and induced weight loss in people with Type 2 diabetes, the company ...